Abstracts Archive - Page 1245 of 2425 - ACR Meeting Abstracts

Abstract Number: 592 • 2017 ACR/ARHP Annual Meeting
Which Imaging Outcomes for AxSpA Are Most Sensitive to Change? a 5-Year Analysis of the DESIR Cohort
Alexandre Sepriano¹, Sofia Ramiro², Désirée van der Heijde¹, Maxime Dougados³, Pascal Claudepierre⁴, Antoine Feydy⁵, M. Reijnierse⁶, Damien Loeuille⁷ and Robert B.M. Landewé⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Paris-Descartes University,, Paris, France, ⁴Hôpital Henri Mondor, Créteil, France, ⁵Univ. Paris Descartes, PRES Sorbonne Paris Cité, Service de radiologie B, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, Paris, France, ⁶Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France, ⁸University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands
Background/Purpose: Several imaging outcomes have become available to assess inflammation and structural damage over time in patients with axial spondyloarthris (axSpA). However, no formal comparison…
Abstract Number: 593 • 2017 ACR/ARHP Annual Meeting
Progression of Structural Damage on MRI in Patients with Axial Spondyloarthritis Is Limited: The 5 –Year Results in the DESIR Cohort
Alexandre Sepriano¹, Sofia Ramiro², Robert B.M. Landewé³, Maxime Dougados⁴ and Désirée van der Heijde¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁴Paris-Descartes University,, Paris, France
Background/Purpose: Reliably detecting radiographic structural change in patients with axial spondyloarthritis (axSpA), especially in the sacroiliac joints (SIJ), is notoriously difficult. Magnetic resonance imaging (MRI)…
Abstract Number: 594 • 2017 ACR/ARHP Annual Meeting
Imaging Biomarkers in Crohn’s Associated Axial Spondyloarthritis
Fardina Malik¹, John A. Carrino², Madeline Epsten³, Ellen Scherl⁴, Stephanie Wichuk⁵, Ulrich Weber⁶, Susanne J Pedersen⁷, Joel Paschke⁸, Jackie Szymonifka³, Georg Kroeber⁹, Randy Longman⁴, Walter P. Maksymowych⁵ and Lisa A. Mandl³, ¹Rheumatology, Hospital For Special Surgery, New York, NY, ²Radiology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Gastroenterology, Weill Cornell Medical College, New York, NY, ⁵Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁷Copenhagen Center for Arthritis Research, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark, ⁸CARE Arthritis, Edmonton, AB, Canada, ⁹University of Southern Denmark, Odense, Denmark
Background/Purpose: Axial SpA has been reported in 4-16% of patients with Crohn's disease (CD). However, some plain radiograph or magnetic resonance imaging (MRI) studies in…
Abstract Number: 595 • 2017 ACR/ARHP Annual Meeting
Improved Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Abatacept: Results from a Phase III Trial
Vibeke Strand¹, E Alemao², T Lehman², A Johnsen², S Banerjee², HA Ahmad² and Philip J Mease³, ¹Stanford University, Palo Alto, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: In the Phase III ASTRAEA study (NCT01860976), abatacept (ABA) significantly increased ACR20 responses, alleviating musculoskeletal symptoms in patients (pts) with active psoriatic arthritis (PsA).1…
Abstract Number: 596 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis: Results from 2 Phase 3 Studies
Vibeke Strand¹, Kurt de Vlam², Jose A Covarrubias-Cobos³, Philip J Mease⁴, Dafna D Gladman⁵, Thijs Hendrikx⁶, Elizabeth Kudlacz⁷, Daniela Graham⁷, Joseph Wu⁷, Joseph C Cappelleri⁷ and Ming-Ann Hsu⁷, ¹Stanford University, Palo Alto, CA, ²UZ Leuven, Leuven, Belgium, ³Unidad Reumatologica Las Americas S.C.P, Yucatán, Mexico, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Safety and efficacy were investigated in 2 Phase…
Abstract Number: 597 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
Arthur Kavanaugh¹, Helena Marzo-Ortega², Ronald Vender³, Julie Birt⁴, David Adams⁴, Olivier Benichou⁴, Chen-Yen Lin⁴ and Peter Nash⁵, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ³Dermatrials Research, Inc., Hamilton, ON, Canada, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. Up to 24 weeks, IXE was superior to placebo (PBO) in improving…
Abstract Number: 598 • 2017 ACR/ARHP Annual Meeting
Efficacy of Ustekinumab in Psoriatic Arthritis Patients By Prior Treatment Exposure and Disease Duration
Arthur Kavanaugh¹, Soumya D. Chakravarty^2,3, G. James Morgan⁴, M. Isabel Apaolaza⁵, Shelly Kafka², Elizabeth C. Hsia^6,7, Michael Song⁷, Yin You⁷ and Iain B. McInnes⁸, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Drexel University College of Medicine, Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Spring House, PA, ⁵Janssen Biologics BV, Leiden, Netherlands, ⁶University of Pennsylvania School of Medicine, Philadelphia, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸University of Glasgow, Glasgow, United Kingdom
Background/Purpose: To evaluate the efficacy of ustekinumab (UST) by prior treatment exposure and disease duration in adult PsA patients (pts) in the Phase 3 trials…
Abstract Number: 599 • 2017 ACR/ARHP Annual Meeting
Intravenous Golimumab in Adult Patients with Active Psoriatic Arthritis: Efficacy and Safety through Week 24
Arthur Kavanaugh¹, M. Elaine Husni², Diane D. Harrison³, Lilianne Kim³, Kim Hung Lo³ and Elizabeth C. Hsia⁴, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Rheumatology, Cleveland Clinic, Cleveland, OH, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA
Background/Purpose: The GO-VIBRANT study was designed to evaluate the safety and efficacy of intravenous (IV) golimumab (GLM) in adult patients (pts) with active PsA (biologic-naïve).…
Abstract Number: 600 • 2017 ACR/ARHP Annual Meeting
Low Rates of Major Adverse Cardiac Events, Malignancies, and Serious Infections in Subjects with Psoriasis and Psoriatic Arthritis Treated with Apremilast for ≥156 Weeks: Pooled Analysis from the Esteem and Palace 1-3 Phase 3 Trials
Arthur Kavanaugh¹, Matthias Augustin², Eric Lespessailles³, Kim A. Papp⁴, Maria Paris⁵, Rongdean Chen⁵, Dafna D Gladman⁶, David M. Pariser⁷ and Ketty Peris⁸, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Institute for Health Care Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ³University of Orleans, Orleans, France, ⁴Probity Medical Research, Waterloo, ON, Canada, ⁵Celgene Corporation, Summit, NJ, ⁶Toronto Western Hospital, Toronto, ON, Canada, ⁷Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, ⁸Catholic University of Rome, Rome, Italy
Background/Purpose: Apremilast (APR), an oral PDE4 inhibitor, was effective in phase 3, randomized, placebo (PBO)-controlled trials assessing treatment of moderate to severe plaque psoriasis (ESTEEM…
Abstract Number: 601 • 2017 ACR/ARHP Annual Meeting
Long-Term (4-Year) Efficacy and Safety of Apremilast Monotherapy in DMARD-Naive Subjects with Active Psoriatic Arthritis
Alvin F. Wells¹, Christopher J. Edwards², Alan J. Kivitz³, Paul Bird⁴, Dianne Nguyen⁵, Maria Paris⁵, Lichen Teng⁵ and Jacob A. Aelion⁶, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University Hospital Southampton, Southampton, United Kingdom, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴University Of New South Wales, Sydney, Australia, ⁵Celgene Corporation, Summit, NJ, ⁶West Tennessee Research Institute, Jackson, TN
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune responses that cause joint inflammation and other manifestations of psoriatic arthritis…
Abstract Number: 602 • 2017 ACR/ARHP Annual Meeting
Improvements in Work Productivity with up to 104 Weeks of Apremilast Monotherapy: Results from a Phase 3b, Randomized, Controlled Study in Biologic-NaïVe Subjects with Active Psoriatic Arthritis
Philip J Mease¹, Dafna D Gladman², Eric K Davenport³, Xiaolei Zhou³, Benoit Guerette⁴, Lichen Teng⁴, Satyin Kaura⁴ and Peter Nash⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³RTI Health Solutions, Research Triangle Park, NC, ⁴Celgene Corporation, Summit, NJ, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Patients with active psoriatic arthritis (PsA) may experience disease manifestations across multiple domains, as well as impaired functioning in daily activities at home and…
Abstract Number: 603 • 2017 ACR/ARHP Annual Meeting
Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials
Philip J Mease¹, Dafna D Gladman², Arthur Kavanaugh³, Priscila Nakasato⁴, Benoit Guerette⁴, Lichen Teng⁴ and Peter Nash⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of California, San Diego, School of Medicine, La Jolla, CA, ⁴Celgene Corporation, Summit, NJ, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: The PALACE 1, 2, and 3 trials evaluated the efficacy and safety of apremilast (APR) in subjects with active psoriatic arthritis (PsA) despite prior…
Abstract Number: 604 • 2017 ACR/ARHP Annual Meeting
Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies
Philip J Mease¹, Dafna D Gladman², Juan J. Gomez-Reino³, Stephen Hall⁴, Arthur Kavanaugh⁵, Eric Lespessailles⁶, Georg Schett⁷, Maria Paris⁸, Lichen Teng⁸ and Jürgen Wollenhaupt⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶University of Orleans, Orleans, France, ⁷Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁸Celgene Corporation, Summit, NJ, ⁹Schön Klinik Hamburg-Eilbek, Klinik fur Rheumatologie, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, regulates immune activity in psoriatic arthritis (PsA) patients. We evaluated the long-term safety of APR treatment for…
Abstract Number: 605 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Exhibits a Favorable Safety Profile during 24 Weeks of Treatment in Subjects with Active Psoriatic Arthritis: Integrated Safety Analysis of Two Randomized, Placebo Controlled, Phase III Clinical Trials
Philip J Mease¹, Gerd R. Burmester², Susan Moriarty³, Olivier Benichou³, Wen Xu³ and Peter Nash⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets IL-17A. The objective of this analysis is to report the integrated safety of…
Abstract Number: 606 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Consistent Safety over Long-Term Exposure in Patients with Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Philip J Mease¹, Iain B. McInnes², Kristian Reich³, Peter Nash⁴, Mats Andersson⁵, Ken Abrams⁶, Luminita Pricop⁶ and Todd Fox⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, United Kingdom, ³Dermatologikum Hamburg, Hamburg, Germany, ⁴University of Queensland, Brisbane, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Pooled safety data from secukinumab psoriasis (PSO) and psoriatic arthritis (PsA) clinical trial programs after ~1 year of exposure have been reported previously.1, 2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].